Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03075527 · FLOW

Participant flow

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
    id
    FG000
    title
    Tremelimumab + Durvalumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Progression/Relapse
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients were enrolled from April 2017 to August 2018.
Complete source fields
groups
  1. description
    Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
    id
    FG000
    title
    Tremelimumab + Durvalumab
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Progression/Relapse
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Patients were enrolled from April 2017 to August 2018.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice